TY - JOUR
T1 - METS-IR and all-cause mortality in Korean over 60 years old
T2 - Korean genome and epidemiology study-health examinees (KoGES-HEXA) cohorts
AU - Ryu, Ha Eun
AU - Jung, Dong Hyuk
AU - Heo, Seok Jae
AU - Park, Byoungjin
AU - Lee, Yong Jae
N1 - Publisher Copyright:
Copyright © 2024 Ryu, Jung, Heo, Park and Lee.
PY - 2024
Y1 - 2024
N2 - Background: The metabolic score for insulin resistance index (METS-IR) is a novel non insulin-based marker that indicates the risk for metabolic syndrome and type 2 diabetes mellitus (T2DM). However, METS-IR has not been investigated in relation to all–cause mortality. We investigated the longitudinal effect of METS-IR on all–cause mortality in a significantly large cohort of Korean adults over 60 years old. Methods: Data were assessed from 30,164 Korean participants over 60 years of age from the Korean Genome and Epidemiology Study-Health Examinees (KoGES-HEXA) cohort data, linked with the death certificate database of the National Statistical Office. The participants were grouped into three according to METS-IR tertiles. We used multivariate Cox proportional-hazard regression models to prospectively assess hazard ratios (HRs) for all-cause mortality with 95% confidence intervals (CIs) over an 11-year postbaseline period. Results: During the mean 11.7 years of follow-up, 2,821 individuals expired. The HRs of mortality for METS-IR tertiles were 1.16 (95% CI, 1.01–1.34) in T3 after adjustment for metabolic parameters, but the T2 did not show statistical significance towards increases for incident mortality respectively. In subgroup analysis depending on the cause of mortality, higher METS-IR was associated with cancer mortality (HR, 1.23, 95% CI, 1.01–1.51) but not with cardiovascular mortality (HR, 1.14, 95% CI, 0.83–1.57) after adjustment for the same confounding variables. Conclusion: The METS-IR may be a useful predictive marker for all-cause mortality and cancer mortality, but not for cardiovascular mortality in subjects over 60 years of age. This implies that early detection and intervention strategies for metabolic syndrome could potentially benefit this identified group.
AB - Background: The metabolic score for insulin resistance index (METS-IR) is a novel non insulin-based marker that indicates the risk for metabolic syndrome and type 2 diabetes mellitus (T2DM). However, METS-IR has not been investigated in relation to all–cause mortality. We investigated the longitudinal effect of METS-IR on all–cause mortality in a significantly large cohort of Korean adults over 60 years old. Methods: Data were assessed from 30,164 Korean participants over 60 years of age from the Korean Genome and Epidemiology Study-Health Examinees (KoGES-HEXA) cohort data, linked with the death certificate database of the National Statistical Office. The participants were grouped into three according to METS-IR tertiles. We used multivariate Cox proportional-hazard regression models to prospectively assess hazard ratios (HRs) for all-cause mortality with 95% confidence intervals (CIs) over an 11-year postbaseline period. Results: During the mean 11.7 years of follow-up, 2,821 individuals expired. The HRs of mortality for METS-IR tertiles were 1.16 (95% CI, 1.01–1.34) in T3 after adjustment for metabolic parameters, but the T2 did not show statistical significance towards increases for incident mortality respectively. In subgroup analysis depending on the cause of mortality, higher METS-IR was associated with cancer mortality (HR, 1.23, 95% CI, 1.01–1.51) but not with cardiovascular mortality (HR, 1.14, 95% CI, 0.83–1.57) after adjustment for the same confounding variables. Conclusion: The METS-IR may be a useful predictive marker for all-cause mortality and cancer mortality, but not for cardiovascular mortality in subjects over 60 years of age. This implies that early detection and intervention strategies for metabolic syndrome could potentially benefit this identified group.
KW - METS-IR
KW - aging
KW - cancer
KW - cardiovascular disease
KW - insulin resistance
KW - mortality
UR - http://www.scopus.com/inward/record.url?scp=85189354126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85189354126&partnerID=8YFLogxK
U2 - 10.3389/fendo.2024.1346158
DO - 10.3389/fendo.2024.1346158
M3 - Article
AN - SCOPUS:85189354126
SN - 1664-2392
VL - 15
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1346158
ER -